Asia
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
As its core semiconductor and smartphone businesses slow down, South Korea’s Samsung Group has announced a broad investment into new areas. Those areas include artificial intelligence (AI), 5G mobile technology, electronic components for the automotive industry, and biopharmaceuticals.
Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.
China is the largest supplier of active pharmaceutical ingredients (API) in the world, supplying 40 percent of APIs to global pharma companies. And a recent series of scandals and issues related to drug manufacturing in China has highlighted how many problems this could cause the global drug supply chain.
Ironwood Pharmaceuticals, located in Cambridge, Massachusetts, released its second-quarter financial report and updated its business activities. Key among the announcements was the termination of a license deal with AstraZeneca for its lesinurad franchise.
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
Impact Therapeutics, headquartered in Nanjing, China, completed a Series C financing round worth $30 million. The round was led by Decheng Capital with participating from Lilly Asian Ventures (LAV).
Israel-based Teva Pharmaceutical’s second-quarter financial report led off with a dramatic 18 percent drop in quarterly revenue compared to the same period the year before. The company reported second-quarter sales of $4.7 billion.
A Minnesota woman, Denise Miley, is suing Bristol-Myers Squibb and Otsuka Pharmaeutical, alleging that their Abilify (aripiprazole) for depression and anxiety, caused a gambling impulse. Her suit isn’t the only one.
BeiGene, a biotech company based in Beijing, China and Cambridge, Massachusetts, announced it priced its initial public offering (IPO) on the Hong Kong stock exchange.
PRESS RELEASES